Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683512 | 1.00 | CSNK2A1 (0.50) | CSNK2A1HCRTR1HCRTR2KDM4EHTT | |
| SCHEMBL16656573 | 0.86 | HCRTR1 (0.49) | HCRTR1HCRTR2KMT2A | |
| SCHEMBL11920220 | 0.86 | CSNK2A1 (0.46) | CSNK2A1KDM4EHTTDHODHSMN1; SMN2 | |
| SCHEMBL19241426 | 0.85 | HCRTR1 (0.48) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL16277289 | 0.84 | ALDH1A1 (0.45) | CSNK2A1HCRTR1HCRTR2KDM4EHTT | |
| SCHEMBL1421933 | 0.82 | CYP46A1 (0.64) | HCRTR1HCRTR2KDM4EHTTTDP1 | |
| SCHEMBL29814525 | 0.82 | KDM4E (0.47) | CSNK2A1HCRTR1KDM4EHTTDHODH | |
| SCHEMBL9955206 | 0.82 | KDM4E (0.47) | CSNK2A1HCRTR1KDM4EHTTDHODH | |
| SCHEMBL4621112 | 0.81 | CSNK2A1 (0.65) | CSNK2A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL16803311 | 0.81 | HCRTR2 (0.48) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | claimed |
| CN-117820238-A | Method for preparing 2- (2-pyrimidinyl) -5-methylbenzoic acid | 苏州莱克施德药业有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116635392-A | Substituted azabicyclooctane compounds, intermediates thereof and methods of making | 上海海雁医药科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| WO-2022111683-A1 | SUBSTITUTED AZABICYCLOOCTANE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE AND PREPARATION METHOD THEREFOR | 上海海雁医药科技有限公司 | 2022-06-02 | — | — | WO | claimed |
| CN-112480107-A | Substituted azabicyclooctane compounds, intermediates therefor and processes for their preparation | 上海海雁医药科技有限公司 | 2021-03-12 | — | — | CN | claimed |
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | disclosed |
| CN-122010922-A | Benzoxazole compounds, pharmaceutical compositions containing same and uses thereof | 株洲千金药业股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12583841-B2 | Tetrahydropyrrolocyclic compound and application thereof | Breakthrough Pharmaceuticals Inc. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4289834-B1 | TETRAHYDROPYRROLOCYCLIC COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| EP-2152690-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009143033-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143033-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008147518-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147518-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | CSNK2A1 4197/4885HCRTR1 2/4885HCRTR2 1/4885 |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CSNK2A1 3486/4885HCRTR1 2/4885HCRTR2 1/4885 |
| US-12583841-B2 | Tetrahydropyrrolocyclic compound and application thereof | HCRTR2, HCRTR1, CRHR2 | CSNK2A1 266/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.